Aurinia Pharmaceuticals Inc (AUPH)

$5.68

+0.08

(+1.43%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $5.59
    $5.70
    $5.68
    downward going graph

    1.58%

    Downside

    Day's Volatility :1.93%

    Upside

    0.35%

    downward going graph
  • $4.71
    $12.43
    $5.68
    downward going graph

    17.08%

    Downside

    52 Weeks Volatility :62.11%

    Upside

    54.3%

    downward going graph

Returns

PeriodAurinia Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
14.05%
6.5%
0.0%
6 Months
-29.91%
7.1%
0.0%
1 Year
-49.5%
9.8%
0.0%
3 Years
-48.76%
14.2%
-20.2%

Highlights

Market Capitalization
810.9M
Book Value
$2.5
Earnings Per Share (EPS)
-0.43
PEG Ratio
0.0
Wall Street Target Price
10.86
Profit Margin
-32.69%
Operating Margin TTM
-13.06%
Return On Assets TTM
-8.1%
Return On Equity TTM
-16.69%
Revenue TTM
191.4M
Revenue Per Share TTM
1.33
Quarterly Revenue Growth YOY
46.2%
Gross Profit TTM
83.4M
EBITDA
-47.0M
Diluted Eps TTM
-0.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.07
EPS Estimate Next Year
0.47
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.02

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Aurinia Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 91.2%

Current $5.68
Target $10.86

Company Financials

FY18Y/Y Change
Revenue
463.0K
↑ 10.24%
Net Income
-64.1M
↓ 9.42%
Net Profit Margin
-13.8K%
↑ 3006.43%
FY19Y/Y Change
Revenue
318.0K
↓ 31.32%
Net Income
-123.8M
↑ 93.15%
Net Profit Margin
-38.9K%
↓ 25096.47%
FY20Y/Y Change
Revenue
50.1M
↑ 15660.38%
Net Income
-102.7M
↓ 17.09%
Net Profit Margin
-204.88%
↑ 38740.4%
FY21Y/Y Change
Revenue
45.6M
↓ 9.0%
Net Income
-181.0M
↑ 76.24%
Net Profit Margin
-396.81%
↓ 191.93%
FY22Y/Y Change
Revenue
134.0M
↑ 193.89%
Net Income
-108.2M
↓ 40.22%
Net Profit Margin
-80.71%
↑ 316.1%
FY23Y/Y Change
Revenue
175.5M
↑ 30.95%
Net Income
-78.0M
↓ 27.88%
Net Profit Margin
-44.45%
↑ 36.26%
Q4 FY22Q/Q Change
Revenue
28.4M
↓ 49.02%
Net Income
-26.0M
↑ 189.75%
Net Profit Margin
-91.6%
↓ 75.48%
Q1 FY23Q/Q Change
Revenue
34.4M
↑ 21.01%
Net Income
-26.2M
↑ 0.61%
Net Profit Margin
-76.16%
↑ 15.44%
Q2 FY23Q/Q Change
Revenue
41.5M
↑ 20.59%
Net Income
-11.5M
↓ 56.15%
Net Profit Margin
-27.7%
↑ 48.46%
Q3 FY23Q/Q Change
Revenue
54.5M
↑ 31.38%
Net Income
-13.4M
↑ 17.01%
Net Profit Margin
-24.67%
↑ 3.03%
Q4 FY23Q/Q Change
Revenue
45.1M
↓ 17.28%
Net Income
-26.9M
↑ 99.86%
Net Profit Margin
-59.6%
↓ 34.93%
Q1 FY24Q/Q Change
Revenue
50.3M
↑ 11.55%
Net Income
-10.7M
↓ 60.0%
Net Profit Margin
-21.37%
↑ 38.23%
FY18Y/Y Change
Total Assets
145.9M
↓ 23.17%
Total Liabilities
33.3M
↑ 38.1%
FY19Y/Y Change
Total Assets
326.7M
↑ 123.97%
Total Liabilities
53.2M
↑ 59.72%
FY20Y/Y Change
Total Assets
463.7M
↑ 41.93%
Total Liabilities
55.9M
↑ 5.16%
FY21Y/Y Change
Total Assets
543.4M
↑ 17.19%
Total Liabilities
64.3M
↑ 14.96%
FY22Y/Y Change
Total Assets
470.9M
↓ 13.34%
Total Liabilities
65.4M
↑ 1.79%
FY23Y/Y Change
Total Assets
548.1M
↑ 16.4%
Total Liabilities
170.1M
↑ 160.0%
Q4 FY22Q/Q Change
Total Assets
470.9M
↓ 3.57%
Total Liabilities
65.4M
↑ 0.86%
Q1 FY23Q/Q Change
Total Assets
451.8M
↓ 4.06%
Total Liabilities
61.4M
↓ 6.22%
Q2 FY23Q/Q Change
Total Assets
548.9M
↑ 21.5%
Total Liabilities
156.6M
↑ 155.26%
Q3 FY23Q/Q Change
Total Assets
555.0M
↑ 1.11%
Total Liabilities
163.1M
↑ 4.17%
Q4 FY23Q/Q Change
Total Assets
548.1M
↓ 1.25%
Total Liabilities
170.1M
↑ 4.27%
Q1 FY24Q/Q Change
Total Assets
516.6M
↓ 5.73%
Total Liabilities
157.2M
↓ 7.61%
FY18Y/Y Change
Operating Cash Flow
-51.6M
↑ 25.36%
Investing Cash Flow
-65.0K
↓ 99.19%
Financing Cash Flow
4.0M
↓ 97.71%
FY19Y/Y Change
Operating Cash Flow
-63.5M
↑ 22.95%
Investing Cash Flow
7.8M
↓ 12073.85%
Financing Cash Flow
243.7M
↑ 5971.95%
FY20Y/Y Change
Operating Cash Flow
-69.9M
↑ 10.09%
Investing Cash Flow
-158.2M
↓ 2132.46%
Financing Cash Flow
194.4M
↓ 20.25%
FY21Y/Y Change
Operating Cash Flow
-157.7M
↑ 125.73%
Investing Cash Flow
-103.9M
↓ 34.34%
Financing Cash Flow
221.1M
↑ 13.76%
FY22Y/Y Change
Operating Cash Flow
-79.5M
↓ 49.57%
Investing Cash Flow
-60.6M
↓ 41.63%
Financing Cash Flow
2.4M
↓ 98.9%
Q4 FY22Q/Q Change
Operating Cash Flow
10.5M
↓ 168.02%
Investing Cash Flow
-3.0M
↓ 93.99%
Financing Cash Flow
688.0K
↓ 2982.04%
Q1 FY23Q/Q Change
Operating Cash Flow
-31.7M
↓ 403.06%
Investing Cash Flow
24.9M
↓ 923.72%
Financing Cash Flow
1.6M
↑ 138.23%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.8M
↓ 91.08%
Investing Cash Flow
-5.6M
↓ 122.56%
Financing Cash Flow
1.1M
↓ 30.45%

Technicals Summary

Sell

Neutral

Buy

Aurinia Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
1.63%
-29.91%
-49.5%
-48.76%
-9.97%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
NA
NA
0.0
0.07
-0.17
-0.08
NA
2.5
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
Buy
$810.9M
-9.97%
NA
-32.69%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Aurinia Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 45.09M → 50.30M (in $), with an average increase of 10.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -26.87M → -10.74M (in $), with an average increase of 150.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 111.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 235.3%

Institutional Holdings

  • Armistice Capital, LLC

    8.57%

  • BlackRock Inc

    6.06%

  • NEA Management Company, LLC

    2.78%

  • State Street Corporation

    1.94%

  • Goldman Sachs Group Inc

    1.50%

  • Nuveen Asset Management, LLC

    1.44%

Company Information

aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.

Organization
Aurinia Pharmaceuticals Inc
Employees
300
CEO
Mr. Peter S. Greenleaf M.B.A.
Industry
Health Technology

Discover More

FAQs